Alpine Immune Sciences, Inc. (ALPN): Price and Financial Metrics

Alpine Immune Sciences, Inc. (ALPN): $11.02

0.06 (+0.55%)

POWR Rating

Component Grades













Add ALPN to Watchlist
Sign Up

Industry: Biotech


of 493

in industry

ALPN Stock Summary

  • ALPN's price/sales ratio is 28.04; that's higher than the P/S ratio of 92.01% of US stocks.
  • As for revenue growth, note that ALPN's revenue has grown 436.49% over the past 12 months; that beats the revenue growth of 98.44% of US companies in our set.
  • Alpine Immune Sciences Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -23.45%, greater than the shareholder yield of merely 10.97% of stocks in our set.
  • Stocks that are quantitatively similar to ALPN, based on their financial statements, market capitalization, and price volatility, are SRRK, EDIT, GLYC, SGMO, and CMRX.
  • ALPN's SEC filings can be seen here. And to visit Alpine Immune Sciences Inc's official web site, go to

ALPN Stock Price Chart Interactive Chart >

Price chart for ALPN

ALPN Price/Volume Stats

Current price $11.02 52-week high $16.37
Prev. close $10.96 52-week low $2.58
Day low $10.20 Volume 60,399
Day high $11.08 Avg. volume 119,811
50-day MA $11.92 Dividend yield N/A
200-day MA $10.48 Market Cap 263.18M

Alpine Immune Sciences, Inc. (ALPN) Company Bio

Alpine Immune Sciences, Inc. is focused on developing novel protein‐based immunotherapies using its proprietary Variant Ig Domain vIgD platform technology. The vIgD platform is designed to interact with multiple targets, including many present in the immune synapse. Alpine’s vIgDs are developed using a process known as directed evolution, which can potentially produce proteins capable of either enhancing or diminishing an immune response and thereby may potentially apply therapeutically to both oncology and inflammatory diseases. The company formed following a July, 2017 merger with Nivalis Therapeutics.

ALPN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$11.02$12.5 14%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Alpine Immune Sciences Inc. To summarize, we found that Alpine Immune Sciences Inc ranked in the 58th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 14.5% on a DCF basis. In terms of the factors that were most noteworthy in this DCF analysis for ALPN, they are:

  • As a business, ALPN is generating more cash flow than merely 23.58% of positive cash flow stocks in the Healthcare.
  • Alpine Immune Sciences Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 23.8% of US stocks with positive free cash flow.
  • Alpine Immune Sciences Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -35.06. This coverage rate is greater than that of only 3.51% of stocks we're observing for the purpose of forecasting via discounted cash flows.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ALPN, try BDX, PKI, MOH, PCRX, and CRHM.

ALPN Latest News Stream

Event/Time News Detail
Loading, please wait...

ALPN Latest Social Stream

Loading social stream, please wait...

View Full ALPN Social Stream

Latest ALPN News From Around the Web

Below are the latest news stories about Alpine Immune Sciences Inc that investors may wish to consider to help them evaluate ALPN as an investment opportunity.

Is the Options Market Predicting a Spike in Alpine (ALPN) Stock?

Investors need to pay close attention to Alpine (ALPN) stock based on the movements in the options market lately.

Yahoo | April 16, 2021

Alpine Immune Sciences Presents Clinical and Preclinical Oncology Program Updates at AACR Virtual Annual Meeting I

Alpine Immune Sciences Presents Clinical and Preclinical Oncology Program Updates at AACR Virtual Annual Meeting I

Yahoo | April 12, 2021

Alpine Immune Sciences (NASDAQ:ALPN) Is Using Debt Safely

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Yahoo | March 21, 2021

Alpine Immune Sciences (NASDAQ:ALPN) Announces Earnings Results

Alpine Immune Sciences (NASDAQ:ALPN) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.31) by $0.04, MarketWatch Earnings reports. Alpine Immune Sciences had a negative net margin of 606.16% and a negative return on equity of 80.38%. ALPN stock […]

Transcript Daily | March 19, 2021

Alpine Immune Sciences, Inc. (ALPN) Q4 2020 Earnings Call Transcript

Good afternoon, ladies and gentlemen, and thank you for joining the Alpine Immune Sciences fourth-quarter 2020 financial results and corporate update conference call. With me on today's call from Alpine Immune Sciences are Executive Chairman and CEO Dr. Mitchell Gold; President and Head of Research and Development Dr. Stanford Peng; Chief Financial Officer Paul Rickey; and Chief Business Officer, Dr.

Yahoo | March 19, 2021

Read More 'ALPN' Stories Here

ALPN Price Returns

1-mo -13.57%
3-mo -17.08%
6-mo 38.79%
1-year 239.08%
3-year 39.32%
5-year -40.37%
YTD -12.54%
2020 228.13%
2019 4.35%
2018 -67.14%
2017 25.00%
2016 -71.06%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.1931 seconds.